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 Abstract 
Background: Creatinine based estimated glomerular filtration rate (eGFR) determines chronic kidney 
disease (CKD) stage, but under estimates renal function. The 2014 updated NICE guidance 
recommends that GPs reduce over diagnosis of CKD stage 3a (eGFR 45 – 60 ml/min/1.73m2) by using 
the renal biomarker cystatin C.  
Aim: To determine the population requirement for cystatin C testing compared with the current 
national availability of the assay.  
Design and setting: Retrospective study of primary care laboratory requests in Oxfordshire 
Method: We analysed first creatinine results from tests ordered in primary care over a six year 
period (2008 – 2014) in a population of 600,000 in Oxfordshire. We determined the number of 
patients with CKD stage 3a without proteinuria (requiring cystatin C to implement NICE guidance). A 
conservative estimate of the national need was provided by scaling the population of Oxfordshire to 
the national population (CKD prevalence is below the national average). We determined cystatin C 
assay availability using national databases of laboratory assay provision.  
Results From a population of 600,000, there were 22,240 individuals with stable stage 3a CKD and 
no proteinuria. As the population of Oxfordshire represents 1% of the UK population, there is an 
initial requirement for at least 2 million people to have their CKD status determined with cystatin C 
testing. Eight laboratories reported cystatin C assay provision (2.1% of UK laboratories). 
Conclusion: There is a substantial gap between cystatin C assay requirement in primary care and 
national assay provision. This is a major barrier to implementing NICE guidance. 
 
 
 How this fits in 
• Cystatin C based eGFR improves accuracy of CKD staging and is recommended by NICE 
• We have determined the large scale of cystatin C testing that will be needed for accurate 
diagnosis in primary care 
• A tiny proportion of UK laboratories can test for cystatin C 
• Unless commissioners address this assay provision gap, NICE guidance can’t be implemented 
leaving patients at risk of over diagnosis, unnecessary prescribing and unnecessary 
laboratory monitoring 
 
 
 
 
 
 
 
 
 
 
 
 
 Introduction 
Chronic kidney disease (CKD) increases mortality and healthcare resource usage1 and the majority of 
patients with CKD are diagnosed and managed in general practice. CKD is staged according to 
estimated glomerular filtration rate (eGFR) and level of proteinuria.2 eGFR is routinely calculated 
from serum creatinine, which is cheap to analyse and universally available, but at higher levels of 
measured GFR, the eGFR formulae have a tendency to under-estimate true renal function.3 This 
results in over-diagnosis of CKD and in itself increases costs to healthcare and unnecessary burden 
for patients.  
Cystatin C is an alternative biomarker of renal function, which displays less variation due to muscle 
mass than creatinine and offers greater accuracy of GFR estimation which improves the relationship 
between eGFR and subsequent risk of CKD-related outcomes - cardiovascular death and end-stage 
renal failure.4 
In the UK, the National Institute for Health and Care Excellence (NICE) has published revised 
guidance for the diagnosis and monitoring of CKD.5 Recognising that the newly recommended CKD-
EPI equation for estimating eGFR from creatinine still has bias at higher levels of eGFR3, NICE 
recommend testing with cystatin C for patients whose eGFR calculated from serum creatinine is in 
the stage 3a range (45 – 59 ml/min/1.73m2). Whilst there are many formulae that can transform 
cystatin C into eGFR,6-10 the NICE guidance recommends the CKD-EPIcys equation which combines 
creatinine and cystatin C.5 Use of the CKDEPIcys equation to determine eGFR in large prospective 
cohort studies improves the classification of risk compared with the standard creatinine based CKD-
EPI equation.4 
Irrespective of the choice of equation to transform cystatin C, there is likely to be a substantial need 
for UK laboratories to offer cystatin C testing to general practice at substantial scale and pace if NICE 
guidance is to be implemented within a reasonable time frame. We set out to determine the likely 
population need for cystatin C testing and to compare this with the current scale of provision using 
two indicators of laboratory availability of the assay. 
Methods 
We determined the proportion of patients in primary care in a population of 600,000 in 
Oxfordshire11 who would require testing with cystatin C as part of CKD diagnosis and monitoring in 
accordance with NICE guidance. We analysed first creatinine results from tests ordered in primary 
care over a six year period (2008 – 2014) to assess the scale of the need for cystatin C testing and the 
stability of this requirement over time. The clinical biochemistry laboratory at the John Radcliffe 
Hospital used a modified Jaffe analytical technique with materials traceable to isotope dilution mass 
spectrometry methods, so creatinine assay results were standardised throughout the time period of 
analysis. We calculated eGFR from creatinine using the CKD-EPI equation and we determined the 
number of patients with stable stage 3a CKD -  patients with a minimum of two eGFR results in the 
3a range (45 – 60 ml/min/1.73m2) at least three months apart. For patients with a first eGFR result in 
the 3a range in the last sampled year, 2014, we looked for follow up tests in the 12 months after the 
end of the sampling window in order to determine whether they had stable 3a CKD... We then 
excluded patients with an albumin:creatinine ratio greater than 3 mg/mmol as these patients are 
deemed to have CKD and do not need additional testing with cystatin C.5 Therefore the ‘catch up’ 
testing required in the population to meet NICE guidance would be the remaining patients with 
stable  stage 3a CKD without proteinuria.  
Two indicators of cystatin C assay availability were obtained. UK laboratories are required to 
participate in proficiency testing to achieve accreditation. The United Kingdom External Quality 
Assessment Service (UKNEQAS) represents a network of proficiency testing schemes, one of which 
offers clinical laboratories a service to assess the performance of markers of GFR including creatinine 
and cystatin C. We ascertained from the scheme provider the number of laboratories participating in 
the UKNEQAS quality assessment scheme for both cystatin C and creatinine at two time points one 
year apart to assess for growth in capacity. The second approach was to search for cystatin C on the 
website AssayFinder,12 a widely used web resource that enables identification providers of specific 
laboratory testing.  
Results  
From 2008-2014, a total of 29,987 individuals had evidence of stable stage 3a CKD. Of these, 7,747 
patients had an ACR > 3mg/mmol, leaving 22,240 patients without evidence of proteinuria. In 
addition, a further 3,875 patients had one eGFR in the stage 3a range but no further blood tests 
within the 6 year sampling frame. 
Table 1 shows the numbers of patients with stable 3a CKD in each year and the number with an ACR 
> 3 mg/mmol. The number of new individuals requiring cystatin C testing falls each year as 
population coverage of prevalent cases increases with time from different blood testing practices in 
the community. As the population of Oxfordshire represents around 1% of the UK population, 11 and 
assuming that the level of primary care blood testing is similar in other areas of the UK, there is an 
initial requirement for at least 2 million people to have their CKD status determined with cystatin C 
testing. 
As of April 2015, four laboratories reported cystatin C on the UKNEQAS scheme for GFR estimations 
compared to 340 reporting creatinine, representing 1.2 % of participating laboratories. In June 2016 
the comparative enrolment was 8 reporting cystatin C and 378 reporting creatinine, 2.1 % of 
participants. In April 2015 the AssayFinder website documented three UK laboratories offering 
cystatin C analysis and this figure was unchanged by July 2016.   
Discussion 
Summary 
A substantial number of patients will require additional testing with cystatin C if the latest NICE CKD 
guidance is to be implemented. Although we observed a reduction, over a 5 year period, in the 
proportion of all eGFR results from primary care that are in the CKD 3a range, there were still large 
numbers of patients whose CKD status cannot be fully determined with creatinine-based measures 
alone. Our findings from two independent estimates of routine cystatin C availability suggest that 
only a few laboratories have this assay available with an accredited testing process and there has 
been very little increase in availability over the past 12 months. This implies that there is a very large 
gap between need for the cystatin C assay, in order to implement NICE guidance, and its provision in 
routine UK healthcare. 
Strengths and Limitations 
Limitations of our assessment of cystatin C test availability using the enrolment in UKNEQAS include 
the possibility that UK laboratories are enrolled with different scheme providers.  We are aware 
through our own laboratory participation of another proficiency testing organisation, the Swedish 
EQUALIS scheme, which provides a service across Europe. Five of the 51 participating laboratories 
were in the UK.. The limitation of using AssayFinder as an indicator is that not all UK laboratories use 
this website. However, despite the potential limitation of our approaches the two indicators are 
consistent in suggesting only very limited provision. Cystatin C can be undertaken on a wide range of 
commonly available instruments6 suggesting this is not a factor in routine availability. Furthermore, 
whilst our estimate of the UK wide requirement for cystatin C testing rests on a number of 
assumptions, we believe that it is a conservative estimate, given that the prevalence of CKD in 
Oxfordshire is lower than the average for clinical commissioning group regions in England.13  
Nevertheless our analysis has significant strengths. We took a population-based approach to include 
all patients who are currently tested and monitored in primary care over time, allowing us to 
determine the population to which the NICE guidance is applicable. Standardised creatinine assays 
were used by the laboratory during 2008 – 2014 so there will be very little variation over time in 
laboratory methods and we used the CKD-EPI formula to calculate eGFR, in keeping with the most 
recent recommendation from NICE. 
Comparison with existing literature 
To our knowledge, there has been no other attempt to quantify the need for cystatin C testing in a 
contemporary patient population with renal function testing by general practitioners. Furthermore 
there has been very little published on the barriers to implementing current NICE guidance for CKD 
in primary care. 
Implications for clinical practice 
Cystatin C testing is only provided in a small minority of clinical chemistry laboratories at present and 
this represents a significant barrier to implementing the diagnostic algorithm of the new NICE 
guidance for primary care. Nationally, this means that there are large numbers of patients whose 
CKD status cannot be determined according to current NICE guidance on the diagnosis and 
management of CKD.  
This raises a major issue for GPs because they will be unable to meet a national recommendation 
and therefore could be seen to fail their patients, according to this NICE criterion of optimal 
assessment of renal health. However, this is due to a lack of access to a diagnostic test, the 
availability of which was not mandated by NICE prior to the release of the guidance. This exemplifies 
a general problem which arises when guidelines are released without prior assessment of the 
practical requirements for their implementation. There are strategies that can minimise this 
problem, notably the Dutch College of General Practitioners has a well-established programme of 
producing evidence-based guidelines with education and professional development, alongside 
ensuring that there is adequate access to the investigations that are recommended.14 
We suggest that Clinical Commissioning Groups should identify how best to commission diagnostic 
services to support GPs in implementing NICE guidance to ensure accurate diagnosis and monitoring 
of CKD in their registered populations. 
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Table 1 Number of individuals with stable CKD stage 3a by year of first test, sub group with 
proteinuria and cumulative total over a six year testing window. 
Year Individuals with 
evidence of stable CKD 
3a 
Individuals with ACR > 3 
mg/mmol 
Cumulative total with 
stable 3a CKD who 
would require cystatin C 
testing 
2008 20129 5094 15035 
2009 4195 1159 18071 
2010 2208 624 19655 
2011 1146 317 20484 
2012 988 219 21253 
2013 735 202 21786 
2014 586 132 22240 
 
